Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + domvanalimab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zimberelimab + domvanalimab is a combination of two investigational monoclonal antibodies developed for cancer immunotherapy. Zimberelimab is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that binds to PD-1, aiming to restore the anti-tumor activity of T cells. Domvanalimab is an Fc-silent monoclonal antibody targeting the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint receptor on immune cells that acts as a brake on anticancer immune responses. By blocking TIGIT, domvanalimab frees up immune pathways and activates immune cells to attack cancer without depleting regulatory T cells. The combination targets both PD-1 and TIGIT checkpoints, which play complementary roles in suppressing anti-tumor immunity, thereby enhancing overall immune activation against tumors. This regimen is being evaluated in multiple phase 3 clinical trials for various cancers including non-small cell lung cancer (NSCLC) and gastrointestinal cancers[4][5][6].
- Other names
- Domvanalimab and ZimberelimabAnti-TIGIT + Anti-PD-1 combination
02
Targets
TIGIT (T cell immunoreceptor with Ig and ITIM domains)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on zimberelimab + domvanalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + domvanalimab.